Cargando…

Mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs

BACKGROUND: Trials evaluating drug discontinuation (drug discontinuation trials, DDTs) show a broad methodological spectrum. There are several specific methodological aspects in drug discontinuation trials (e.g., determination of research question; configuration of intervention; definition of outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Grede, Nina, Kuss, Katrin, Staudt, Ina, Donner-Banzhoff, Norbert, Viniol, Annika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878942/
https://www.ncbi.nlm.nih.gov/pubmed/36703178
http://dx.doi.org/10.1186/s13063-023-07105-6
_version_ 1784878596780720128
author Grede, Nina
Kuss, Katrin
Staudt, Ina
Donner-Banzhoff, Norbert
Viniol, Annika
author_facet Grede, Nina
Kuss, Katrin
Staudt, Ina
Donner-Banzhoff, Norbert
Viniol, Annika
author_sort Grede, Nina
collection PubMed
description BACKGROUND: Trials evaluating drug discontinuation (drug discontinuation trials, DDTs) show a broad methodological spectrum. There are several specific methodological aspects in drug discontinuation trials (e.g., determination of research question; configuration of intervention; definition of outcomes). To verify this specifies, we did a scoping review about the study designs of drug discontinuation trials. METHODS: A systematic literature search in Medline (PubMed), The Cochrane Library, EMBASE, CINAHL, Web of Science, and PsycINFO was performed. In a two-step selection process, we identified DDTs, which evaluate the discontinuation of one or more long-term medication as the investigated intervention, by two independent reviewers. Besides bibliographic data, we extracted several parameters to describe the used study design of the included DDTs: motivation for DDT, initially treatment aim of the discontinued medication, study design, methods of discontinuation, follow-up times, number of study participants, and outcome parameter. RESULTS: Out of 12,132 records, we included 581 DDTs. The most common motivation for doing a DDT were expected side effects (48.8%), the motivation of proving the efficacy of medication (21.6%), or doubts on the expected benefit of the used medication (13.8%). The majority of the discontinued medication was initially prescribed to improve the prognosis of a chronic disease (60.4%) or to relieve symptoms (31%). The study designs of the trials showed a broad methodological spectrum. The minority of the drug discontinuation trials were randomized controlled trials (34%). CONCLUSION: The results of this scoping review illustrates the need for an evidence-based methodological standard for planning and conducting drug discontinuation trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-023-07105-6.
format Online
Article
Text
id pubmed-9878942
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98789422023-01-27 Mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs Grede, Nina Kuss, Katrin Staudt, Ina Donner-Banzhoff, Norbert Viniol, Annika Trials Review BACKGROUND: Trials evaluating drug discontinuation (drug discontinuation trials, DDTs) show a broad methodological spectrum. There are several specific methodological aspects in drug discontinuation trials (e.g., determination of research question; configuration of intervention; definition of outcomes). To verify this specifies, we did a scoping review about the study designs of drug discontinuation trials. METHODS: A systematic literature search in Medline (PubMed), The Cochrane Library, EMBASE, CINAHL, Web of Science, and PsycINFO was performed. In a two-step selection process, we identified DDTs, which evaluate the discontinuation of one or more long-term medication as the investigated intervention, by two independent reviewers. Besides bibliographic data, we extracted several parameters to describe the used study design of the included DDTs: motivation for DDT, initially treatment aim of the discontinued medication, study design, methods of discontinuation, follow-up times, number of study participants, and outcome parameter. RESULTS: Out of 12,132 records, we included 581 DDTs. The most common motivation for doing a DDT were expected side effects (48.8%), the motivation of proving the efficacy of medication (21.6%), or doubts on the expected benefit of the used medication (13.8%). The majority of the discontinued medication was initially prescribed to improve the prognosis of a chronic disease (60.4%) or to relieve symptoms (31%). The study designs of the trials showed a broad methodological spectrum. The minority of the drug discontinuation trials were randomized controlled trials (34%). CONCLUSION: The results of this scoping review illustrates the need for an evidence-based methodological standard for planning and conducting drug discontinuation trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-023-07105-6. BioMed Central 2023-01-26 /pmc/articles/PMC9878942/ /pubmed/36703178 http://dx.doi.org/10.1186/s13063-023-07105-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Grede, Nina
Kuss, Katrin
Staudt, Ina
Donner-Banzhoff, Norbert
Viniol, Annika
Mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs
title Mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs
title_full Mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs
title_fullStr Mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs
title_full_unstemmed Mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs
title_short Mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs
title_sort mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878942/
https://www.ncbi.nlm.nih.gov/pubmed/36703178
http://dx.doi.org/10.1186/s13063-023-07105-6
work_keys_str_mv AT gredenina mappingthemethodologicaldiversityofpublisheddrugdiscontinuationstudiesascopingreviewofstudytopicsobjectivesanddesigns
AT kusskatrin mappingthemethodologicaldiversityofpublisheddrugdiscontinuationstudiesascopingreviewofstudytopicsobjectivesanddesigns
AT staudtina mappingthemethodologicaldiversityofpublisheddrugdiscontinuationstudiesascopingreviewofstudytopicsobjectivesanddesigns
AT donnerbanzhoffnorbert mappingthemethodologicaldiversityofpublisheddrugdiscontinuationstudiesascopingreviewofstudytopicsobjectivesanddesigns
AT viniolannika mappingthemethodologicaldiversityofpublisheddrugdiscontinuationstudiesascopingreviewofstudytopicsobjectivesanddesigns